<DOC>
	<DOCNO>NCT01355874</DOCNO>
	<brief_summary>Primary Objective : To evaluate effect iferanserin ointment cessation bleeding administer intra-anally twice daily ( BID ) 7 14 day subject symptomatic internal hemorrhoid . Methodology : Double-Blind : Phase 3 , multicenter , double-blind , randomize , parallel group , placebo-controlled part study . Extension : Multicenter , open-label part study . Study Treatment Duration : Double-Blind : 28 day ( 14-day treatment period 14-day follow-up period ) . Extension : 12 month ( open-label part study schedule visit every three month . Subjects recurrence ( ) symptomatic internal hemorrhoid treat open-label iferanserin 7 day follow 21-day follow-up period ) . Criteria Evaluation : Primary Endpoint : The primary endpoint cessation bleed end Day 7 persists remainder treatment period ( Day 14 ) .</brief_summary>
	<brief_title>Efficacy Safety Study Treat Subjects With Symptomatic Internal Hemorrhoids</brief_title>
	<detailed_description>Primary Objective : To evaluate effect iferanserin ointment cessation bleeding administer intra-anally twice daily ( BID ) 7 14 day subject symptomatic internal hemorrhoid . Safety Secondary Objective To determine safety iferanserin ointment administer intra-anally BID 7 14 day subject symptomatic internal hemorrhoid . Exploratory Objectives : To evaluate frequency recurrence bleed subject symptomatic internal hemorrhoid . To evaluate time bleed recurrence subject symptomatic internal hemorrhoid . To evaluate efficacy iferanserin ointment treatment recurrence administer intra-anally BID 7 day subject symptomatic internal hemorrhoid . To evaluate parameter Symptom Satisfaction Questionnaire Methodology : Double-Blind : Phase 3 , multicenter , double-blind , randomize , parallel group , placebo-controlled part study . Extension : Multicenter , open-label part study . Criteria Evaluation : Primary Endpoint : The primary endpoint cessation bleed end Day 7 persists remainder treatment period ( Day 14 ) . Secondary Endpoints : Key Secondary Endpoints Cessation itch end Day 7 persists remainder treatment period ( Day 14 ) . Cessation pain end Day 7 persists remainder treatment period ( Day 14 ) . Safety Secondary Endpoints Adverse event ( AEs ) . Serious Adverse event ( SAEs ) . Physical examination . Hematology , serum chemistry , urinalysis . Vital sign . Electrocardiogram . Exploratory Endpoints : Bleeding recurrence rate symptomatic internal hemorrhoid . Time bleed recurrence symptomatic internal hemorrhoid . Response open-label iferanserin ointment treatment recurrence symptomatic internal hemorrhoid . Overall improvement score parameter Symptom Satisfaction Questionnaire .</detailed_description>
	<mesh_term>Hemorrhoids</mesh_term>
	<criteria>1.1 Inclusion Criteria DoubleBlind Recurrence 1 . Males nonpregnant female , age ≥ 18 ≤ 75 year . 2 . Symptomatic internal hemorrhoid , Grades IIII direct anoscopic visualization ( anoscopic visualization require Grade determine colonoscopy within 28 day prior Day 1 ) . 3 . Bleeding hemorrhoid two consecutive day prior randomization ( Day 1 ) . • For female experience menses , two day prior randomization must confirm blood anus menses gently insert cotton swab anus attempt bowel movement ; must see blood cotton swab two consecutive day prior randomization meet inclusion criterion . 4 . Itching OR pain two consecutive day prior randomization ( Day 1 ) . 5 . Able attempt bowel movement daily ( define try bowel movement sit toilet least minute , least daily , whether feel need bowel movement day ) . 6 . Body mass index ≥ 18.5 ≤ 36 kg/m2 . 7 . Female nonchildbearing potential , include female : ) hysterectomy , b ) bilateral oophorectomy , c ) bilateral tubal ligation ) post menopausal ( demonstration total cessation menses ≥ 1 year date screen visit ) . 8 . Females child bear potential agree use two form contraception , one must barrier method , full duration study . 9 . Able communicate adequately investigator comply requirement entire study . 10 . Capable use IVRS adequately communicate comprehension IVRS question investigator . 11 . Capable freely willing provide write informed consent prior participate study . 1 . 1.2 Exclusion Criteria DoubleBlind Recurrence 1 . Grade IV internal hemorrhoid . 2 . Age ≥ 40 year , complete colon evaluation within three year . 3 . Age &lt; 40 year , sigmoidoscopy complete colon evaluation within three year . 4 . Age &lt; 40 year , follow complete colon evaluation within two year ; age ≥ 40 year , follow complete colon evaluation within one year : History adenomatous polyp . Family history either colorectal cancer colorectal adenoma diagnose firstdegree relative age 60 . Family history genetic test indicate presence one two hereditary syndrome . 5 . Malignancy within 5 year prior Day 1 ( exception treat basal cell/squamous cell carcinoma skin ) . 6 . History inflammatory bowel disease . 7 . History irritable bowel syndrome constipation diarrhea . 8 . Previous surgical instrumental treatment internal hemorrhoid . 9 . Clinical evidence history fecal incontinence . 10 . Current thrombose internal external hemorrhoid ( ) . 11 . Clinical evidence history anal fissure . 12 . Clinical evidence history anal fistula . 13 . AST/ALT &gt; 3x ULN . 14 . Hemoglobin &lt; 10.0 g/dL . 15 . Selective serotonin reuptake inhibitor within 28 day prior Day 1 . 16 . Tamoxifen within 28 day prior Day 1 . 17 . Laxatives ( unless maintain stable dose medication ≥ 60 day prior Day 1 ) . 18 . Anticoagulants ( e.g. , coumadin , heparinoids , dabigatran ) within 90 day prior Day 1 . 19 . Antiplatelet agent low dose aspirin ( unless maintain medication ≥ 90 day prior Day 1 ) . 20 . Over counter prescription antihemorrhoid agent ( include herbal supplement ) within 14 day prior Day 1 . 21 . Topical anesthetic within 14 day prior Day 1 . 22 . Chronic use analgesic ( e.g. , opioids , acetaminophen , aspirin , NSAIDS , cox2 inhibitor , etc ) . 23 . Any investigational agent within 28 day prior Day 1 ( exception iferanserin recurrence ) . 24 . AntiTNF agent within 6 month prior Day 1 . 25 . Oral parenteral steroid within 28 day prior Day 1 . 26 . Use anal , intraanal , intrarectal steroid within 28 day prior Day 1 . 27 . Expected plan interventional and/or surgical procedure require hospitalization , colonoscopy , sigmoidoscopy ( colonoscopy sigmoidoscopy screen period acceptable ) . 28 . Following concomitant disease state : Clinical evidence history significant cardiovascular disease include arrhythmia , clinically significant ECG abnormality , myocardial infarction , stroke , congestive heart failure ( great class II ) , valve disease abnormality . Asthma currently require treatment ( exception infrequent use rescue inhaler ) . Clinical evidence history chronic renal failure ( great Stage III ) . Clinical evidence history gastric ulcer , duodenal ulcer , pancreatitis . Clinical evidence history hematological disease . Clinical evidence history neurological disease . Acute infection currently require treatment . Clinical evidence history chronic infectious disease . 29 . Major organ transplant . 30 . Any disease prior surgery may interfere subject successfully complete study . 31 . History prior anal rectal surgery ( hemorrhoid band 5 year Day 1 ) . 32 . Psychosis , schizophrenia , mania , depressive disorder , history suicide attempt suicidal ideation , psychiatric illness ( exception intermittent anxiety ) . 33 . Known sensitivity investigational product ( ) class investigational product ( ) . 34 . Drug alcohol abuse within 12 month Day 1 . 35 . Currently use narcotic ( ) chronically . 36 . Breastfeeding female . 37 . Females menstrual cycle discern whether bleed rectal bleed vaginal bleeding menstruation . 38 . Employees , family member , student investigator clinical site .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Internal Symptomatic Hemorrhoids</keyword>
</DOC>